Covid-19 Living Data

Study registration: *
Publication Skowronski D, Clin Infect Dis, 2021
Dates: 2020-12-31 to 2021-05-01
Funding: No specific funding (No external funding was provided for this work.)
Conflict of interest: Yes (D. M. S. is Principal or co-Investigator on grants from the Michael Smith Foundation for Health Research, the Public Health Agency of Canada, and the Canadian Institutes of Health Research paid to her institution and unrelated to the current work. M. K. received grants/contracts paid to his institution from Roche, Hologic, and Siemens, unrelated to this work. M. S. has been an investigator on projects, unrelated to the current work, funded by GlaxoSmithKline, Merck, Pfizer, Sanofi- Pasteur, Seqirus, Symvivo (Investigator on grant for COVID-19 vaccine trial), and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.)

Methods
Methods	Study design:Test-negative Description of participants: Elderly aged 70 and older in communities in British Colombia, Canada Inclusion criteria: Community-dwelling adults ≥ 70 years old in British Columbia with record of a single dose of mRNA vaccine on or before the date of specimen collection or no record of vaccination Specimens collected between 4 April (epidemiological week 14) and 1 May (week 17) 2021 and tested by real-time reverse-transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2. Exclusion criteria: Specimens missing information for age, sex, health authority, specimen collection date, vaccination date, or vaccine type Specimens that were tested outside of public funding Clients who received more than 1 vaccine dose those who received a viral vector vaccine specimens identified within Public Health Laboratory Operations Viewer and Reporter (PLOVER) database and/ or the provincial immunization registry (PIR) or notifiable disease list from long-term care facility (LTCF), assisted-living or independent-living facilities. Follow-up duration (months): 4.03
Vaccines:	1 dose of BNT162b2 or mRNA-1273
Variant description :
Variant description :	Variant name: Alpha Evidence: Direct evidence (effectiveness determined by sequencing cases)
Documents available	Protocol NR Statistical plan No Data-sharing stated: NR Data accessibility: Correspondence: D. M. Skowronski MD, FRCPC, 655 West 12th Ave, Vancouver, British Columbia, V5Z 4R4, Canada (danuta.skowronski@bccdc.ca).
General comment	Concerns regarding uncontrolled confounding and bias in selection of participants into the study.